Qiagen N.V. (QGEN) Stock Score, Valuation & Financial Research
Qiagen N.V. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 44/100.
Quick answer for QGEN
Qiagen N.V. currently has a Wall Street Score of 44/100. The stored market price is $42.02. Its financial score is 30/100. Its valuation score is 16/100. The latest WSS change is -0.8 points. These figures are a research snapshot, not a buy or sell recommendation.
What Qiagen N.V. does
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted disease
QGEN financial snapshot
- Wall Street Score:
- 44/100
- Current price:
- $42.02
- Market capitalization:
- $8.67B
- Revenue:
- $2.10B
- Net income:
- $402.2M
- Free cash flow:
- $453.3M
- Cash:
- $646.3M
- Total debt:
- $1.65B
- EPS:
- 2.04
- P/E ratio:
- 20.6x
- Financial score:
- 30/100
- Valuation score:
- 16/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $453.3M, showing positive cash generation.
- The balance sheet shows $646.3M of cash versus $1.65B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.8 points: QGEN decreased 0.8 points because Capital declined by 2 points, Valuation declined by 5 points.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 30/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research QGEN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.